Table 10.
Selected immunotherapy approaches clinically approved for treatment of NHL.
| Class of Agents/Agent | Targeted Structure | Effective in NHL Subtypes |
|---|---|---|
| Monospecific monoclonal antibodies | ||
| Rituximab | CD20 | All B-NHL [11,12] |
| Obinutuzumab | CD20 | CLL/SLL [13], FL frontline [14], R/R FL [15] |
| Tafasitamab | CD19 | R/R B-NHL [26], R/R DLBCL [27] |
| Alemtuzumab | CD52 | Mycosis fungoides [33], T-PLL [34] |
| Mogamulizumab | CCR4 | Adult T-cel leukemia/lymphoma [37,38] |
| Bispecific monoclonal antibodies | ||
| Blinatumomab | CD3-CD19 | R/R B-NHL [48] R/R DLBCL [49,50] |
| Mosunetuzumab | CD3-CD20 | R/R B-NHL [52] |
| Glofitamab | CD3-CD20 | R/R B-NHL [56,57] |
| Checkpoint inhibitors | ||
| Pembrolizumab | PD-1 | R/R PMBCL [80,81], Richter’s syndrome [93], mycosis fungoides [95] |
| Nivolumab | PD-1 | R/R PMBCL [83], PCNSL and PTL [77] |
| Pidilizumab | PD-1 | DLBCL after autologous SCT [75] |
| CAR-T cells | ||
| Tisagenlecleucel | CD19 | R/R aggressive NHL [141] |
| Axicabtagene ciloleucel | CD19 | R/R aggressive NHL [142,143] |
| Lisocabtagene maraleucel | CD19 | R/R aggressive NHL [144] |
| Brexucabtagene autoleucel | CD19 | R/R MCL [150] |
| Immunomodulatory agents | ||
| Lenalidomide | Cereblon | R/R FL and MZL [180] MCL frontline [182,183], R/R PCNSL [184], R/R DLBCL [185] |
| Avadomide | Cereblon | R/R DLBCL [194] |
Abbreviations: B-NHL = B-non Hodgkin’s lymphoma, CLL/SLL = chronic lymphocytic leukemia/small lymphocytic lymphoma, FL = follicular lymphoma, R/R = relapsed/refractory, DLBCL = diffuse large B-cell lymphoma, T-PLL = T-prolymphocytic leukemia, PMBCL = primary mediastinal B-cell lymphoma, PCNSL = primary central nervous system lymphoma, PTL = primary testicular lymphoma, SCT = stem cell transplantation, MCL = mantle cell lymphoma, MZL = marginal zone lymphoma.